Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

BACKGROUND: Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously treated advanced squamous (SQ) and non‐squamou...

Descripción completa

Detalles Bibliográficos
Autores principales: Horinouchi, Hidehito, Nishio, Makoto, Hida, Toyoaki, Nakagawa, Kazuhiko, Sakai, Hiroshi, Nogami, Naoyuki, Atagi, Shinji, Takahashi, Toshiaki, Saka, Hideo, Takenoyama, Mitsuhiro, Katakami, Nobuyuki, Tanaka, Hiroshi, Takeda, Koji, Satouchi, Miyako, Isobe, Hiroshi, Maemondo, Makoto, Goto, Koichi, Hirashima, Tomonori, Minato, Koichi, Sumiyoshi, Naoki, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718542/
https://www.ncbi.nlm.nih.gov/pubmed/31353840
http://dx.doi.org/10.1002/cam4.2411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718542/
https://www.ncbi.nlm.nih.gov/pubmed/31353840
http://dx.doi.org/10.1002/cam4.2411

Ejemplares similares